tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.21292/2075-1230-2022-100-3-53-60tiblj-1626Research ArticleОБЗОРREVIEWПерспективы расширения медикаментозной терапии туберкулеза с множественной и широкой лекарственной устойчивостьюProspects for Expanding Drug Therapy for Multiple Drug Resistant and Extensively Drug Resistant TuberculosisМожокинаГ. Н.MozhokinaG. N.

Можокина Галина Николаевна, доктор медицинских наук, ведущий научный сотрудник лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции

127473, Москва, ул. Достоевского, д. 4, к. 2

Galina N. Mozhokina, Doctor of Medical Sciences, Leading Researcher of Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection

Build. 2, 4, Dostoevskiy St., Moscow, 127473

mojokina@mail.ruСамойловаА. Г.SamoylovA. G.

Самойлова Анастасия Геннадьевна, доктор медицинских наук, заместитель директора по научной работе

127473, Москва, ул. Достоевского, д. 4, к. 2

Anastasiya G. Samoylova, Doctor of Medical Sciences, Deputy Director for Research

Build. 2, 4, Dostoevskiy St., Moscow, 127473

a.samoilova.nmrc@mail.ruВасильеваИ. А.VasilyevaI. А.

Васильева Ирина Анатольевна, доктор медицинских наук, профессор, директор.

Тел.: + 7 (495) 631-15-15, доб. 1001

127473, Москва, ул. Достоевского, д. 4, к. 2

Irina A. Vasilyeva, Doctor of Medical Sciences, Professor, Director

Build. 2, 4, Dostoevskiy St., Moscow, 127473

nmrc@nmrc.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious DiseasesRussian Federation20220604202210035360Copyright © Можокина Г.Н., Самойлова А.Г., Васильева И.А., 20222022Можокина Г.Н., Самойлова А.Г., Васильева И.А.Mozhokina G.N., Samoylov A.G., Vasilyeva I.А.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1626

В обзоре представлен анализ 64 публикаций, посвященных перепрофилированным антибиотикам и перспективам их применения для лечения туберкулеза с множественной и широкой лекарственной устойчивостью. Приведены сведения о механизмах действия на микобактерии туберкулеза бета-лактамов и макролидов, результаты клинических исследований и профиля безопасности.

This review analyzes 64 publications on repurposed antibiotics and the prospects of their use in the treatment of multiple drug resistant and extensively drug resistant tuberculosis. The article describes mechanisms of action of beta-lactams and macrolides on tuberculous mycobacteria; the results of studies and safety profiles are given.

микобактерии туберкулезатуберкулез легкихмножественная лекарственная устойчивостьперепрофилирование антибиотиковбета-лактамымакролидыtuberculous mycobacteriapulmonary tuberculosismultiple drug resistanceantibiotic repurposingbeta-lactamsmacrolideReferencesВасильева И. А., Самойлова А. Г., Ловачева О. В., Черноусова Л. Н., Багдасарян Т. Р. Влияние разных противотуберкулезных и антибактериальных препаратов на эффективность лечения больных туберкулезом с множественной лекарственной устойчивостью // Туб. и болезни легких. ‒ 2017. ‒ Т. 95, № 10. ‒ С. 9-16. https://doi.org/10.21292/2075-1230-2017-95-10-9-15.Vasilyeva I.А., Samoylova А.G., Lovacheva O.V., Chernousova L.N., Bagdasaryan T.R. The effect of different TB drugs and antimicrobial agents on the efficacy of treatment of tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 10, pp. 9-16. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-10-9-15.Васильева И. А., Самойлова А. Г., Рудакова А. В., Ловачева О. В., Глебов К. А., Черноусова. Л. Н. Экономическое обоснование применения новых схем химиотерапии для лечения больных туберкулезом с широкой лекарственной устойчивостью // Туб. и болезни легких. ‒ 2018. ‒ Т. 96, № 6. ‒ С. 7-16.Vasilyeva I.А., Samoylova А.G., Rudakova А.V., Lovacheva O.V., Glebov K.А., Chernousova. L.N. Economic feasibility of new chemotherapy regimens for treatment of tuberculosis patients with extensive drug resistance. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 7-16. (In Russ.)Карпов О. И. Макролиды как антивоспалительные агенты. https://medi.ru, 2007.Karpov O.I. Makrolidy kak antivospalitelnye agenty. [Macrolides as anti-inflammatory agents]. https://medi.ru, 2007.Лукьянов С. В. Клиническая фармакология макролидов // Consilium medicum. ‒ 2004. ‒ № 10. ‒ С. 769-773.Lukyanov S.V. Clinical pharmacology of macrolides. Consilium Medicum. 2004, no. 10, pp. 769-773. (In Russ.)Мишин В. Ю., Дейкина О. Н., Андрианова А. Ю., Егорова Н. А. Влияние неспецифических антимикробных препаратов (амоксициллин/клавунат, кларитромицин и имипенем/циластин) на течение туберкулеза легких и внебольничной пневмонии // Пульмонология. ‒ 2013. ‒ № 5. ‒ С. 45-48.Mishin V.Yu., Deykina O.N., Аndrianova А.Yu., Egorova N.А. Use of non-specific antimicrobials (amoxicillin/clavulonate, clarithromycin and imipenem/cilastine) in the treatment of pulmonary tuberculosis and community-acquired pneumonia. Pulmonologiya, 2013, no. 5, pp. 45-48. (In Russ.)Можокина Г. Н., Самойлова А. Г. Кардиотоксические свойства фторхинолонов и бедаквилина // Туб. и болезни легких. ‒ 2019. ‒ Т. 97, № 4. ‒ С. 56-62. doi.org/10.21292/2075-1230-2019-97-4-56-62.Mozhokina G.N., Samoylova А.G. Cardiac toxicity of fluoroquinolones and bedaquiline. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 4, pp. 56-62. (In Russ.) doi.org/10.21292/2075-1230-2019-97-4-56-62.Можокина Г. Н., Самойлова А. Г. Нейротоксические побочные эффекты антимикробных и противотуберкулезных препаратов // Антибиотики и химиотерапия. ‒ 2020. ‒ Т. 65, № 5-6. ‒ С. 78-84. DOI: 10.37489/0235-2990-2020-65-5-6-78-82.Mozhokina G.N., Samoylova А.G. Neurotoxic adverse effects of antimicrobial and anti-tuberculous drugs. Antibiotiki i Khimioterapiya, 2020, vol. 65, no. 5-6, pp. 78-84. (In Russ.) doi: 10.37489/0235-2990-2020-65-5-6-78-82.Русских А. Е., Кутузова Д. М., Ловачева О. В., Самойлова А. Г., Васильева И. А. Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы // Туб. и болезни легких. ‒ 2020. ‒ Т. 98, № 12. С. 57-66. https://doi.org/10.21292/2075-1230-2020-98-12-57-66.Russkikh А.E., Kutuzova D.M., Lovacheva O.V., Samoylova А.G., Vasilyeva I.А. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 12, pp. 57-66. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-12-57-66.Ставицкая Н. В., Фелькер И. Г., Жукова Е. М., Тлиф А. И., Докторова Н. П., Кудлай Д. А. Многофакторный анализ результатов применения бедаквилина в терапии МЛУ/ШЛУ-туберкулеза легких // Туб. и болезни легких. – 2020. – Т. 98, № 7. – С. 56-62.Stavitskaya N.V., Felker I.G., Zhukova E.M., Tlif А.I., Doktorova N.P., Kudlay D.А. The multivariate analysis of the results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 7, pp. 56-62. (In Russ.)Синопальников А. И. Иммуномодулирующие эффекты макролидов: направления возможного клинического применения в пульмонологии // Терапевтический архив. ‒ 2011. ‒ Т. 83, № 8. ‒ С. 10-20.Sinopalnikov А.I. Immunomodulatory effects of macrolides: areas of possible clinical application in pulmonology. Terapevticheskiy Arkhiv, 2011, vol. 83, no. 8, pp. 10-20. (In Russ.)Синопальников А. И. Кардиотоксичность макролидов: фокус на азитромицин (критический анализ). Эффективная фармакотерапия // Пульмонология и оториноларингология. ‒ 2017. ‒ Т. 30, № 3-4. ‒ С. 8-16.Sinopalnikov А.I. Cardiotoxicity of macrolides: focus on azithromycin (critical analysis). Effektivnaya Farmakoterapiya. Pulmonologiya i Otorinolaringologiya, 2017, vol. 30, no. 3-4, pp. 8-16. (In Russ.)Agarwal S. K., Kumar D. Safety and efficacy of linezolid and azithromycin in the treatment of multidrug-resistant tuberculosis // Chest. ‒ 2006. ‒ № 130 (4_MeetingAbstracts): 95S.Agarwal S.K., Kumar D. Safety and efficacy of linezolid and azithromycin in the treatment of multidrug-resistant tuberculosis. Chest, 2006, no. 130 (4_MeetingAbstracts): 95S.Andini N., Nash K. A. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible // Antimicrob. Agents Chemother. ‒ 2006. ‒ № 50. ‒ Р. 2560-2562Andini N., Nash K.A. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob. Agents Chemother., 2006, no. 50, pp. 2560-2562.Bianchet M. A., Pan Y. H., Basta L. A. B., Saavedra H., Lloyd E. P., Kumar P., Mattoo R., Townsend C. A., Lamichhane G. Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase LdtMt2 by biapenem and tebipenem // BMC Biochem. ‒ 2017. ‒ Vol. 18, № 1. ‒ Р. 8.Bianchet M.A., Pan Y.H., Basta L.A.B., Saavedra H., Lloyd E.P., Kumar P., Mattoo R., Townsend C.A., Lamichhane G. Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase LdtMt2 by biapenem and tebipenem. BMC Biochem., 2017, vol. 18, no. 1, pp. 8.Bolhuis M. S., van der Laan T., Kosterink J. G., van der Werf T. S., van Soolingen D., Alffenaar J.-W. C. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis // Eur. Respir. J. ‒ 2014. ‒ № 44. ‒ Р. 808-811.Bolhuis M.S., van der Laan T., Kosterink J.G., van der Werf T.S., van Soolingen D., Alffenaar J.-W.C. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. Eur. Respir. J., 2014, no. 44, pp. 808-811.Bolhuis M. S., van Altena R., van Soolingen D., de Lange W. C. M., Uges D. R. A., van der Werf T., Kosterink J. G. W., Alffenaar J.-W. C. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients // Eur. Respir. J. ‒ 2013. ‒ № 42. ‒ Р. 1614-1621.Bolhuis M.S., van Altena R., van Soolingen D., de Lange W.C.M., Uges D.R.A., van der Werf T., Kosterink J.G.W., Alffenaar J.-W.C. Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur. Respir. J., 2013, no. 42, pp. 1614-1621.Cordillot M., Dubée V., Triboulet S., Dubost L., Marie A., Hugonnet J. E., Arthur M., Mainardi J. L. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems // Antimicrob. Agents. Chemother. ‒ 2013. ‒ Vol. 57, № 12. ‒ Р. 5940-5945.Cordillot M., Dubée V., Triboulet S., Dubost L., Marie A., Hugonnet J.E., Arthur M., Mainardi J.L. In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems. Antimicrob. Agents Chemother., 2013, vol. 57, no. 12, pp. 5940-5945.Correale S., Ruggiero A., Capparelli R., Pedone E., Berisio R. Structures of free and inhibited forms of the L,D-transpeptidase LdtMt1 from Mycobacterium tuberculosis // Acta crystallographica. Section D, Biological crystallography. ‒ 2013. ‒ № 69. ‒ Р. 1697-1706Correale S., Ruggiero A., Capparelli R., Pedone E., Berisio R. Structures of free and inhibited forms of the L,D-transpeptidase LdtMt1 from Mycobacterium tuberculosis. Acta crystallographica. Section D, Biological Crystallography, 2013, no. 69, pp. 1697-1706.Crick D. C., Mahapatra S., Brennan P. J. Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis // Glycobiology. ‒ 2001. ‒ Vol. 11, № 9. ‒ Р. 107R-118R.Crick D.C., Mahapatra S., Brennan P.J. Biosynthesis of the arabinogalactan-peptidoglycan complex of Mycobacterium tuberculosis. Glycobiology, 2001, vol. 11, no. 9, pp. 107R-118R.Deshpande D., Srivastava S., Nuermberger E., Pasipanodya J. G., Swaminathan S., Gumbo T. A. Faropenem, Linezolid, and Moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME Path on the Milky Way // Clin. Infect. Dis. ‒ 2016. ‒ Vol. 63 (suppl. 3). ‒ Р. S95-S101.Deshpande D., Srivastava S., Nuermberger E., Pasipanodya J.G., Swaminathan S., Gumbo T.A. Faropenem, Linezolid, and Moxifloxacin regimen for both drug-susceptible and multidrug-resistant tuberculosis in children: FLAME Path on the Milky Way. Clin. Infect. Dis., 2016, vol. 63, suppl. 3, pp. S95-S101.Deshpande D., Srivastava S., Chapagain M., Magombedze G., Martin K. R., Cirrincione K. N., Lee P. S., Koeuth T., Dheda K., Gumbo T. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis // Sci. Adv. ‒ 2017. ‒ Vol. 3, № 8. ‒ Р. e1701102.Deshpande D., Srivastava S., Chapagain M., Magombedze G., Martin K.R., Cirrincione K.N., Lee P.S., Koeuth T., Dheda K., Gumbo T. Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. Sci. Adv., 2017, vol. 3, no. 8, pp. e1701102.Dhar N., Dubée V., Ballell L., Cuinet G., Hugonnet J. E., Signorino-Gelo F., Barros D., Arthur M., McKinney J. D. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic // Antimicrob. Agents Chemother. ‒ 2015. ‒ Vol. 59, № 2. ‒ Р. 1308-1319.Dhar N., Dubée V., Ballell L., Cuinet G., Hugonnet J.E., Signorino-Gelo F., Barros D., Arthur M., McKinney J.D. Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob. Agents Chemother., 2015, vol. 59, no. 2, pp. 1308-1319.Diacon A. H., van der Merwe L., Barnard M. β-lactams against tuberculosis ‒ new trick for an old dog? // N. Engl. J. Med. ‒ 2016. ‒ Vol. 375, № 4. ‒ Р. 393-394.Diacon A.H., van der Merwe L., Barnard M. β-lactams against tuberculosis ‒ new trick for an old dog? N. Engl. J. Med., 2016, vol. 375, no. 4, pp. 393-394.Dubée V., Triboulet S., Mainardi J. L., Ethève-Quelquejeu M., Gutmann L., Marie A., Dubost L., Hugonnet J. E., Arthur M. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt₁ by carbapenems and cephalosporins // Antimicrob. Agents Chemother. ‒ 2012. ‒ Vol. 8. ‒ Р. 4189-4195.Dubée V., Triboulet S., Mainardi J.L., Ethève-Quelquejeu M., Gutmann L., Marie A., Dubost L., Hugonnet J.E., Arthur M. Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt₁ by carbapenems and cephalosporins. Antimicrob. Agents Chemother., 2012, vol. 8, pp. 4189-4195.Erdemli S. B., Gupta R., Bishai W. R., Lamichhane G., Amzel L. M., Bianchet M. A. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2 // Structure. ‒ 2012. ‒ Vol. 20, № 12. ‒ Р. 2103-2115.Erdemli S.B., Gupta R., Bishai W.R., Lamichhane G., Amzel L.M., Bianchet M.A. Targeting the cell wall of Mycobacterium tuberculosis: structure and mechanism of L,D-transpeptidase 2. Structure, 2012, vol. 20, no. 12, pp. 2103-2115.Global tuberculosis report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.Global tuberculosis report 2020. Geneva, World Health Organization, 2020. Licence: CC BY-NC-SA 3.0 IGO.Gokulan K., Khare S., Cerniglia C. E., Foley S. L., Varughese K. I. Structure and inhibitor specificity of L,D-transpeptidase (LdtMt2) from Mycobacterium tuberculosis and antibiotic resistance: Calcium binding promotes dimer formation // AAPS J. ‒ 2018. ‒ Vol. 20, № 2. ‒ Р. 44.Gokulan K., Khare S., Cerniglia C.E., Foley S.L., Varughese K.I. Structure and inhibitor specificity of L,D-transpeptidase (LdtMt2) from Mycobacterium tuberculosis and antibiotic resistance: Calcium binding promotes dimer formation. AAPS J., 2018, vol. 20, no. 2, pp. 44.Gold B., Smith R., Nguyen Q., Roberts J., Ling Y., Lopez Quezada L., Somersan S., Warrier T., Little D., Pingle M., Zhang D., Ballinger E., Zimmerman M., Dartois V., Hanson P., Mitscher L. A., Porubsky P., Rogers S., Schoenen F. J., Nathan C., Aubé J. Novel cephalosporins selectively active on nonreplicating Mycobacterium tuberculosis // J. Med. Chem. ‒ 2016. ‒ Vol. 59, № 13. ‒ Р. 6027-6044.Gold B., Smith R., Nguyen Q., Roberts J., Ling Y., Lopez Quezada L., Somersan S., Warrier T., Little D., Pingle M., Zhang D., Ballinger E., Zimmerman M., Dartois V., Hanson P., Mitscher L.A., Porubsky P., Rogers S., Schoenen F.J., Nathan C., Aubé J. Novel cephalosporins selectively active on nonreplicating Mycobacterium tuberculosis. J. Med. Chem., 2016, vol. 59, no. 13, pp. 6027-6044.Gonzalo X., Drobniewski F. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate // J. Antimicrob. Chemother. ‒ 2013. ‒ Vol. 68, № 2. ‒ Р. 366-369.Gonzalo X., Drobniewski F. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. J. Antimicrob. Chemother., 2013, vol. 68, no. 2, pp. 366-369.Gun M. A., Bozdogan B., Coban A. Y. Tuberculosis and beta-lactam antibiotics // Future Microbiol. ‒ 2020. ‒ Vol. 15, № 10. ‒ Р. 937-944.Gun M.A., Bozdogan B., Coban A.Y. Tuberculosis and beta-lactam antibiotics. Future Microbiol., 2020, vol. 15, no. 10, pp. 937-944.Horita Y., Maeda S., Kazumi Y., Doi N. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β‐lactamase inhibitors // Antimicrob. Agents Chemother. ‒ 2014. ‒ № 58. ‒ Р. 7010-7014.Horita Y., Maeda S., Kazumi Y., Doi N. In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β‐lactamase inhibitors. Antimicrob. Agents Chemother., 2014, no. 58, pp. 7010-7014.Hugonnet J. E., Tremblay L. W., Boshoff H. I., Barry C. E. 3rd, Blanchard J. S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis // Sci. ‒ 2009. ‒ № 323. ‒ Р. 1215-1218.Hugonnet J.E., Tremblay L.W., Boshoff H.I., Barry C.E. 3rd, Blanchard J.S. Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Sci., 2009, no. 323, pp. 1215-1218.Kaushik A., Ammerman N. C., Tasneen R., Story-Roller E., Dooley K. E., Dorman S. E., Nuermberger E. L., Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis // J. Antimicrob. Chemother. ‒ 2017. ‒ Vol. 72, № 8. ‒ Р. 2320-2325.Kaushik A., Ammerman N.C., Tasneen R., Story-Roller E., Dooley K.E., Dorman S.E., Nuermberger E.L., Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother., 2017, vol. 72, no. 8, pp. 2320-2325.Kim H. S., Kim J., Im H. N., Yoon J. Y., An D. R., Yoon H. J., Kim J. Y., Min H. K., Kim S. J., Lee J. Y., Han B. W., Suh S. W. Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains // Acta Crystallogr. D Biol. Crystallogr. ‒ 2013. ‒ № 69. ‒ Р. 420-431.Kim H.S., Kim J., Im H.N., Yoon J.Y., An D.R., Yoon H.J., Kim J.Y., Min H.K., Kim S.J., Lee J.Y., Han B.W., Suh S.W. Structural basis for the inhibition of Mycobacterium tuberculosis L,D-transpeptidase by meropenem, a drug effective against extensively drug-resistant strains. Acta Crystallogr. D Biol. Crystallogr., 2013, no. 69, pp. 420-431.Klemens S. P., DeStefano M. S., Cynamon M. H. Therapy of multidrugresistant tuberculosis: lessons from studies with mice // Antimicrob. Agents Chemother. ‒ 1993. ‒ № 37. ‒ Р. 2344-2347.Klemens S.P., DeStefano M.S., Cynamon M.H. Therapy of multidrugresistant tuberculosis: lessons from studies with mice. Antimicrob. Agents Chemother., 1993, no. 37, pp. 2344-2347.Kumar P., Arora K., Lloyd J. R.., Lee I. Y., Nair V., Fischer E., Boshoff H. I., Barry C. E. 3rd. Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis // Mol. Microbiol. ‒ 2012. ‒ Vol. 86, № 2. ‒ Р. 367-381.Kumar P., Arora K., Lloyd J.R., Lee I.Y., Nair V., Fischer E., Boshoff H.I., Barry C.E. 3rd. Meropenem inhibits D, D-carboxypeptidase activity in Mycobacterium tuberculosis. Mol. Microbiol., 2012, vol. 86, no. 2, pp. 367-381.Kumar P., Kaushik A., Lloyd E. P., Li S. G., Mattoo R., Ammerman N. C., Bell D. T., Perryman A. L., Zandi T. A., Ekins S., Ginell S. L., Townsend C. A., Freundlich J. S., Lamichhane G. Non-classical transpeptidases yield insight into new antibacterials // Na.t Chem. Biol. ‒ 2017. ‒ Vol. 13, № 1. ‒ Р. 54-61.Kumar P., Kaushik A., Lloyd E.P., Li S.G., Mattoo R., Ammerman N.C., Bell D.T., Perryman A.L., Zandi T.A., Ekins S., Ginell S.L., Townsend C.A., Freundlich J.S., Lamichhane G. Non-classical transpeptidases yield insight into new antibacterials. Nat. Chem. Biol., 2017, vol. 13, no. 1, pp. 54-61.Lavollay M., Arthur M., Fourgeaud M., Dubost L., Marie A., Veziris N., Blanot D., Gutmann L., Mainardi J.-L. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L, D-transpeptidation // J Bacteriol. ‒ 2008. ‒ Vol. 190, № 12. ‒ Р. 4360-4366.Lavollay M., Arthur M., Fourgeaud M., Dubost L., Marie A., Veziris N., Blanot D., Gutmann L., Mainardi J.-L. The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L, D-transpeptidation. J. Bacteriol., 2008, vol. 190, no. 12, pp. 4360-4366.Maitra A., Munshi T., Healy J., Martin L. T., Vollmer W., Keep N. H., Bhakta S. Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles' heel for the TB-causing pathogen // FEMS Microbiol Rev. ‒ 2019. ‒ Vol. 43, № 5. ‒ Р. 548-575.Maitra A., Munshi T., Healy J., Martin L.T., Vollmer W., Keep N.H., Bhakta S. Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles' heel for the TB-causing pathogen. FEMS Microbiol Rev., 2019, vol. 43, no. 5, pp. 548-575.Palomino J. C., Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? // J. Antimicrob. Chemother. ‒ 2012. ‒ № 68. ‒ Р. 275-283.Palomino J.C., Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J. Antimicrob. Chemother., 2012, no. 68, pp. 275-283.Patel H., Calip G. S., DiDomenico R. J., Schumock G. T., Suda K. J., Lee T. A. Comparison of cardiac events associated with Azithromycin vs Amoxicillin // JAMA Netw Open. ‒ 2020. ‒ Vol. 3, № 9. ‒ Р. e2016864.Patel H., Calip G.S., DiDomenico R.J., Schumock G.T., Suda K.J., Lee T.A. Comparison of cardiac events associated with Azithromycin vs Amoxicillin. JAMA Netw Open, 2020, vol. 3, no. 9, pp. e2016864.Payen M. C., Muylle I., Vandenberg O., Mathys V., Delforge M., Van den Wijngaert S., Clumeck N., De Wit S. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases // Int. J. Tuberc Lung Dis. ‒ 2018. ‒ Vol. 22, № 1. ‒ Р. 34-39.Payen M.C., Muylle I., Vandenberg O., Mathys V., Delforge M., Van den Wijngaert S., Clumeck N., De Wit S. Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. Int. J. Tuberc Lung Dis., 2018, vol. 22, no. 1, pp. 34-39.Pushkaran A. C., Vinod V., Vanuopadath M., Nair S. S., Nair S. V., Vasudevan A. K., Biswas R., Mohan C. G. Combination of repurposed drug diosmin with amoxicillin-clavulanic acid causes synergistic inhibition of mycobacterial growth // Sci Rep. ‒ 2019. ‒ Vol. 9, № 1. ‒ 6800.Pushkaran A.C., Vinod V., Vanuopadath M., Nair S.S., Nair S.V., Vasudevan A.K., Biswas R., Mohan C.G. Combination of repurposed drug diosmin with amoxicillin-clavulanic acid causes synergistic inhibition of mycobacterial growth. Sci. Rep., 2019, vol. 9, no. 1, 6800.Ramón-García S., González Del Río R., Villarejo A. S., Sweet G. D., Cunningham F., Barros D., Ballell L., Mendoza-Losana A., Ferrer-Bazaga S., Thompson C. J. Repurposing clinically approved cephalosporins for tuberculosis therapy // Sci. Rep. ‒ 2016. ‒ Vol. 28, № 6. ‒ Р. 34293.Ramón-García S., González Del Río R., Villarejo A.S., Sweet G.D., Cunningham F., Barros D., Ballell L., Mendoza-Losana A., Ferrer-Bazaga S., Thompson C.J. Repurposing clinically approved cephalosporins for tuberculosis therapy. Sci. Rep., 2016, vol. 28, no. 6, pp. 34293.Sauvage E., Kerff F., Terrak M., Ayala J. A., Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis // FEMS Microbiol. Rev. ‒ 2008. ‒ Vol. 32, № 2. ‒ Р. 234-258.Sauvage E., Kerff F., Terrak M., Ayala J.A., Charlier P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis. FEMS Microbiol. Rev., 2008, vol. 32, no. 2, pp. 234-258.Schembri S., Williamson P. A., Short P. M., Singanayagam A., Akram A., Taylor J., Singanayagam A., Hill A. T., Chalmers J. D. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies // BMJ. ‒ 2013. ‒ Vol. 20. ‒ Р. 346:f1235.Schembri S., Williamson P.A., Short P.M., Singanayagam A., Akram A., Taylor J., Singanayagam A., Hill A.T., Chalmers J.D. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies. BMJ, 2013, vol. 20, pp. 346:f1235.Schoonmaker M. K., Bishai W. R., Lamichhane G. Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams // J. Bacteriol. ‒ 2014. ‒ №. 196. ‒ Р. 1394-1402.Schoonmaker M.K., Bishai W.R., Lamichhane G. Nonclassical transpeptidases of Mycobacterium tuberculosis alter cell size, morphology, the cytosolic matrix, protein localization, virulence, and resistance to β-lactams. J. Bacteriol., 2014, no. 196, pp. 1394-1402.Simkó J., Csilek A., Karászi J., Lorincz I. Proarrhythmic potential of antimicrobial agents // Infection. ‒ 2008. ‒ № 36. ‒ Р. 194-206.Simkó J., Csilek A., Karászi J., Lorincz I. Proarrhythmic potential of antimicrobial agents. Infection, 2008, no. 36, pp. 194-206.Solapure S., Dinesh N., Shandil R., Ramachandran V., Sharma S., Bhattacharjee D., Ganguly S., Reddy J., Ahuja V., Panduga V., Parab M., Vishwas K. G., Kumar N., Balganesh M., Balasubramanian V. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis // Antimicrob. Agents Chemother. ‒ 2013. ‒ Vol. 57, № 6. ‒ Р. 2506-2510.Solapure S., Dinesh N., Shandil R., Ramachandran V., Sharma S., Bhattacharjee D., Ganguly S., Reddy J., Ahuja V., Panduga V., Parab M., Vishwas K.G., Kumar N., Balganesh M., Balasubramanian V. In vitro and in vivo efficacy of beta-lactams against replicating and slowly growing/nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2013, vol. 57, no. 6, pp. 2506-2510.Srivastava S., Deshpande D., Pasipanodya J., Nuermberger E., Swaminathan S., Gumbo T. Optimal clinical doses of Faropenem, Linezolid, and Moxifloxacin in children with disseminated tuberculosis: Goldilocks // Clin. Infect. Dis. ‒ 2016. ‒ Vol. 63 (suppl. 3). ‒ Р. S102-S109.Srivastava S., Deshpande D., Pasipanodya J., Nuermberger E., Swaminathan S., Gumbo T. Optimal clinical doses of Faropenem, Linezolid, and Moxifloxacin in children with disseminated tuberculosis: Goldilocks. Clin. Infect. Dis., 2016, vol. 63, suppl. 3, pp. S102-S109.Story-Roller E., Lamichhane G. Have we realized the full potential of β-lactams for treating drug-resistant TB? // IUBMB Life. ‒ 2018. ‒ Vol. 70, № 9. ‒ Р. 881-888. doi: 10.1002/iub.1875.Story-Roller E., Lamichhane G. Have we realized the full potential of β-lactams for treating drug-resistant TB? IUBMB Life, 2018, vol. 70, no. 9, pp. 881-888. doi: 10.1002/iub.1875.Svanström H., Pasternak B., Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study // BMJ. ‒ 2014. ‒ № 349. ‒ g4930.Svanström H., Pasternak B., Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ, 2014, no. 349, g4930.Tiberi S., Payen M. C., Sotgiu G., D'Ambrosio L., Guizado A.V., Migliori G. B. Effectiveness and safety of meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB // Eur. Respir. J. ‒ 2016. ‒ № 47. ‒ Р. 123-1243.Tiberi S., Payen M.C., Sotgiu G., D'Ambrosio L., Guizado A.V., Migliori G.B. Effectiveness and safety of meropenem/clavulanate‐containing regimens in the treatment of MDR‐ and XDR‐TB. Eur. Respir. J., 2016, no. 47, pp. 123-1243.Tiberi S., Sotgiu G., D’Ambrosio L. Effectiveness and safety of imipenem-clavulanate added to an Optimized Background Regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis // Clin. Infect. Dis. ‒ 2016. ‒ Vol. 62, № 9. ‒ Р. 1188-1190.Tiberi S., Sotgiu G., D’Ambrosio L. Effectiveness and safety of imipenem-clavulanate added to an Optimized Background Regimen (OBR) versus OBR control regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. Clin. Infect. Dis., 2016, vol. 62, no. 9, pp. 1188-1190.Truffot-Pernot C., Lounis N., Grosset J. H., Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis // Antimicrob. Agents Chemother. ‒ 1995. ‒ № 39. ‒ Р. 2827-2828.Truffot-Pernot C., Lounis N., Grosset J.H., Ji B. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 1995, no. 39, pp. 2827-2828.Van der Paardt A.-F., Wilffert B., Akkerman O. W., de Lange W. C. M., van Soolingen D., Sinha B., van der Werf T. S., Kosterink J. G. W., Alffenaar J.-W. C. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis // Eur. Respir. J. ‒ 2015. ‒ № 46. ‒ Р. 444-455.Van der Paardt A.-F., Wilffert B., Akkerman O.W., de Lange W.C.M., van Soolingen D., Sinha B., van der Werf T.S., Kosterink J.G.W., Alffenaar J.-W.C. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur. Respir. J., 2015, no. 46, pp. 444-455.Van der Paardt A. L., Akkerman O. W., Gualano G., Palmieri F., Davies Forsman L., Aleksa A., Tiberi S., de Lange W. C., Bolhuis M. S., Skrahina A., van Soolingen D., Kosterink J. G., Migliori G. B., van der Werf T. S., Alffenaar J. C. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis // Eur. Respir J. ‒ 2017. ‒ Vol. 49, № 3. ‒ Р. 1601612.Van der Paardt A.L., Akkerman O.W., Gualano G., Palmieri F., Davies Forsman L., Aleksa A., Tiberi S., de Lange W.C., Bolhuis M.S., Skrahina A., van Soolingen D., Kosterink J.G., Migliori G.B., van der Werf T.S., Alffenaar J.C. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. Eur. Respir J., 2017, vol. 49, no. 3, pp. 1601612.Van Rijn S. P., Zuur M. A., Anthony R., Wilffert B., van Altena R., Akkerman O. W., de Lange W. C. M., van der Werf T. S., Kosterink J. G. W., Alffenaar J. C. Evaluation of carbapenems for treatment of multi- and extensively drug-resistant Mycobacterium tuberculosis // Antimicrob. Agents Chemother. ‒ 2019. ‒ Vol. 63, № 2. ‒ Р. e01489- e014818.Van Rijn S.P., Zuur M.A., Anthony R., Wilffert B., van Altena R., Akkerman O.W., de Lange W.C.M., van der Werf T.S., Kosterink J.G.W., Alffenaar J.C. Evaluation of carbapenems for treatment of multi- and extensively drug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2019, vol. 63, no. 2, pp. e01489- e014818.Volberg W. A., Koci B. J., Su W., Lin J., Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics // J. Pharmacol. Exp. Ther. ‒ 2002. ‒ Vol. 302, № 1. ‒ Р. 320-327.Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther., 2002, vol. 302, no. 1, pp. 320-327.WHO. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva, World Health Organization, 2011.WHO, Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. Geneva, World Health Organization, 2011.WHO consolidated guidelines on drug-resistant tuberculosis treatment ISBN 978-92-4-155052-9 © World Health Organization 2019.WHO consolidated guidelines on drug-resistant tuberculosis treatment ISBN 978-92-4-155052-9 © World Health Organization 2019.Winters N., Butler-Laporte G., Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment // Eur. Respir. J. ‒ 2015. ‒ Vol. 46, № 5. ‒ Р. 1461-1470.Winters N., Butler-Laporte G., Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur. Respir. J., 2015, vol. 46, no. 5, pp. 1461-1470.Working Group on New TB Drugs. WHO Updates Definition of XDR-TB https://www.who .int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis.Working Group on New TB Drugs. WHO Updates Definition of XDR-TB https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis.Xiao S., Guo H., Weiner W. S., Maddox C., Mao C., Gunosewoyo H., Pelly S., White E. L., Rasmussen L., Schoenen F. J., Aubé J., Bishai W. R., Lun S. Revisiting the β-lactams for tuberculosis therapy with a compound-compound synthetic lethality approach // Antimicrob. Agents Chemother. ‒ 2019. ‒ Vol. 63, №11. ‒ Р. e01319-19.Xiao S., Guo H., Weiner W.S., Maddox C., Mao C., Gunosewoyo H., Pelly S., White E.L., Rasmussen L., Schoenen F.J., Aubé J., Bishai W.R., Lun S. Revisiting the β-lactams for tuberculosis therapy with a compound-compound synthetic lethality approach. Antimicrob. Agents Chemother., 2019, vol. 63, no. 11, pp. e01319-19.

The authors declare that there are no conflicts of interest present.